News
Sumitomo Heavy Industries Succeeds in Developing a Superconducting Cyclotron for Proton Therapy
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (President: Shinji Shimomura, hereinafter referred to as "SHI") has conducted proton beam acceleration tests on its in-house developed superconducting
Sumitomo Heavy Industries, Ltd. Obtains Medical Device Approval for Manufacturing and Sales of Accelerator Based BNCT System and the Dose Calculation Program in Japan
Sumitomo Heavy Industries, Ltd. (TOKYO:6302)(President: Shinji Shimomura, referred as SHI hereinafter) has performed clinical trial of the BNCT*1) (Boron Neutron Capture Therapy) system using an
Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy
Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head
SHI receives first order for next-generation proton therapy system from Taichung Veterans General Hospital
Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (head office: Shinagawa City, Tokyo; President and CEO: Shinji Shimomura; hereinafter "SHI") has received an order from Taichung Veterans General